Loading...

OvaScience

DB:3OS
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3OS
DB
$27M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
3OS Share Price and Events
7 Day Returns
2.1%
DB:3OS
-2.2%
DE Biotechs
-3.8%
DE Market
1 Year Returns
-45.2%
DB:3OS
-7.7%
DE Biotechs
-17.5%
DE Market
3OS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OvaScience (3OS) 2.1% -0.9% 2.2% -45.2% -93.2% -
DE Biotechs -2.2% -5.1% -11.9% -7.7% 41.1% -1.1%
DE Market -3.8% -5.7% -9.6% -17.5% -3.6% 8.4%
1 Year Return vs Industry and Market
  • 3OS underperformed the Biotechs industry which returned -7.7% over the past year.
  • 3OS underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
3OS
Industry
5yr Volatility vs Market
Related Companies

3OS Value

 Is OvaScience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OvaScience. This is due to cash flow or dividend data being unavailable. The share price is €0.642.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OvaScience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OvaScience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3OS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.82
NasdaqCM:OVAS Share Price ** NasdaqCM (2018-12-07) in USD $0.74
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 25.33x
Germany Market PE Ratio Median Figure of 413 Publicly-Listed Companies 16.9x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OvaScience.

DB:3OS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:OVAS Share Price ÷ EPS (both in USD)

= 0.74 ÷ -0.82

-0.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OvaScience is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OvaScience is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OvaScience's expected growth come at a high price?
Raw Data
DB:3OS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.19x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.28x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OvaScience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OvaScience's assets?
Raw Data
DB:3OS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $1.25
NasdaqCM:OVAS Share Price * NasdaqCM (2018-12-07) in USD $0.74
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.39x
Germany Market PB Ratio Median Figure of 556 Publicly-Listed Companies 1.79x
DB:3OS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:OVAS Share Price ÷ Book Value per Share (both in USD)

= 0.74 ÷ 1.25

0.59x

* Primary Listing of OvaScience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OvaScience is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OvaScience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OvaScience has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

3OS Future Performance

 How is OvaScience expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OvaScience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OvaScience expected to grow at an attractive rate?
  • Unable to compare OvaScience's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare OvaScience's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare OvaScience's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:3OS Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 48.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3OS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3OS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:3OS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -29 -29
2018-06-30 0 -32 -33
2018-03-31 0 -39 -43
2017-12-31 0 -46 -51
2017-09-30 0 -53 -65
2017-06-30 0 -58 -75
2017-03-31 1 -62 -75
2016-12-31 1 -62 -82
2016-09-30 1 -58 -80
2016-06-30 1 -55 -79
2016-03-31 0 -51 -78
2015-12-31 0 -50 -73

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if OvaScience is high growth as no earnings estimate data is available.
  • Unable to determine if OvaScience is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3OS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from OvaScience Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3OS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:3OS Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.82
2018-06-30 -0.92
2018-03-31 -1.22
2017-12-31 -1.43
2017-09-30 -1.83
2017-06-30 -2.10
2017-03-31 -2.20
2016-12-31 -2.56
2016-09-30 -2.67
2016-06-30 -2.82
2016-03-31 -2.85
2015-12-31 -2.70

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OvaScience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine OvaScience's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. OvaScience's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. OvaScience's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess OvaScience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OvaScience has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

3OS Past Performance

  How has OvaScience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OvaScience's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OvaScience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OvaScience's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OvaScience's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OvaScience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OvaScience Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3OS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.29 -29.28 15.05 10.26
2018-06-30 0.30 -32.97 15.93 12.59
2018-03-31 0.30 -43.45 24.04 15.19
2017-12-31 0.30 -50.98 26.94 18.34
2017-09-30 0.33 -65.09 33.58 19.49
2017-06-30 0.47 -75.02 41.14 20.46
2017-03-31 0.57 -75.40 41.60 21.45
2016-12-31 0.65 -82.26 48.92 21.64
2016-09-30 0.69 -80.22 52.85 21.60
2016-06-30 0.57 -78.85 53.15 20.61
2016-03-31 0.41 -77.77 55.00 18.64
2015-12-31 0.28 -73.22 51.59 18.43
2015-09-30 0.12 -71.51 48.04 21.04
2015-06-30 0.05 -66.51 42.20 22.37
2015-03-31 0.02 -58.91 34.20 22.88
2014-12-31 -49.52 26.15 21.78
2014-09-30 -41.63 18.86 21.80
2014-06-30 -35.60 15.45 19.37
2014-03-31 -31.70 13.84 17.41
2013-12-31 -29.04 13.33 15.44
2013-09-30 -22.24 11.38 10.59
2013-06-30 -18.46 9.24 9.28
2013-03-31 -15.70 7.68 8.06
2012-12-31 -13.51 7.21 6.32
2012-09-30 -11.67 6.59 5.05
2011-12-31 -3.63 1.94 1.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OvaScience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OvaScience has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OvaScience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OvaScience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OvaScience has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

3OS Health

 How is OvaScience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OvaScience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OvaScience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OvaScience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OvaScience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • OvaScience has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OvaScience Company Filings, last reported 2 months ago.

DB:3OS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 44.91 0.00 46.35
2018-06-30 50.21 0.00 53.63
2018-03-31 57.33 0.00 58.30
2017-12-31 64.30 0.00 67.30
2017-09-30 72.29 0.00 75.74
2017-06-30 81.14 0.00 86.56
2017-03-31 94.72 0.00 99.10
2016-12-31 108.22 0.00 114.49
2016-09-30 129.88 0.00 131.00
2016-06-30 146.56 0.00 147.65
2016-03-31 108.84 0.00 110.09
2015-12-31 126.85 0.00 126.66
2015-09-30 142.59 0.00 141.67
2015-06-30 156.71 0.00 155.62
2015-03-31 169.09 0.00 169.34
2014-12-31 55.33 0.00 60.23
2014-09-30 68.63 0.00 72.17
2014-06-30 78.70 0.00 81.37
2014-03-31 86.40 0.00 89.47
2013-12-31 41.70 0.00 44.43
2013-09-30 49.00 0.00 49.57
2013-06-30 54.41 0.00 54.35
2013-03-31 59.06 0.00 59.70
2012-12-31 30.72 0.00 31.39
2012-09-30 34.41 0.00 35.12
2011-12-31 3.82 0.00 4.54
  • OvaScience has no debt.
  • OvaScience has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OvaScience has sufficient cash runway for 2.5 years based on current free cash flow.
  • OvaScience has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of -13.5% each year.
X
Financial health checks
We assess OvaScience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OvaScience has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

3OS Dividends

 What is OvaScience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OvaScience dividends.
If you bought €2,000 of OvaScience shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OvaScience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OvaScience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3OS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3OS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OvaScience has not reported any payouts.
  • Unable to verify if OvaScience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OvaScience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OvaScience has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OvaScience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OvaScience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OvaScience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

3OS Management

 What is the CEO of OvaScience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Kroeger
COMPENSATION $2,430,088
AGE 50
TENURE AS CEO 1.3 years
CEO Bio

Dr. Christopher A. Kroeger, also known as Chris, M.D., MBA has been Chief Executive Officer and Director of OvaScience, Inc. since September 1, 2017 and also serves its President and Secretary. Dr. Kroeger has been a Partner at The Aurora Funds, Inc., since 2007. Dr. Kroeger was a Principal of HyperBranch Medical Technology, Inc. Dr. Kroeger served as Chief Executive Officer and President of Cardioxyl Pharmaceuticals, Inc. since 2008. His professional experience includes as an Associate in corporate development at Genzyme, where he performed scientific and clinical due diligence, market research and financial modeling. Dr. Kroeger has extensive experience leading, building and advising development-stage therapeutic and medical device companies and has a strong clinical and research background as a practicing physician and scientist. Dr. Kroeger has led or co-led syndicated investments. He has significant basic science research experience primarily in signal transduction, including work on the molecular biology and genetics of apoptosis and the transcriptional regulation of Interleukin-2 in human T-cells. He has over seven years of clinical experience in both academic and community hospital practices. Dr. Kroeger also spent four years as a General Surgery Resident at Brigham and Women's Hospital and Harvard Medical School where he was involved in the medical and surgical care of transplant, trauma, vascular, cardiac and general surgical patients. He has over seven years of clinical experience in both academic and community hospital practices and is a licensed physician in North Carolina. Dr. Kroeger also worked at Arthur D. Little in Decision Resources, performing industry analysis for the biotechnology and pharmaceutical industries. He has been a Director of ParinGenix Inc. since August 2006, Cantex Pharmaceuticals, Inc., since August 2006, CardioFocus, Inc. since April 2006. He serves as an Observer on the Boards of Aldagen, Argos, Metastatix and Regado. Dr. Kroeger is also serves on the Boards of the Johns Hopkins Technology Alliance and The University of Maryland Baltimore Commercialization Advisory Board. He served as a Director of The Council for Entrepreneurial Development (CED). He served as Director at Cardioxyl Pharmaceuticals since 2006, Neotropix, Inc., Aurora Funds portfolio companies and HyperBranch Medical Technology Inc. since January 25, 2005. He served as a Director of Regado Biosciences, Inc. He has worked with over a dozen biotechnology and medical device companies during his career. Dr. Kroeger holds an M.D. degree from Stanford University School of Medicine in 1996, a M.B.A. degree from Harvard Business School in June 2003 and a B.A. degree in Biology from Harvard University and his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School.

CEO Compensation
  • Insufficient data for Chris to compare compensation growth.
  • Chris's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OvaScience management team in years:

1.4
Average Tenure
50
Average Age
  • The average tenure for the OvaScience management team is less than 2 years, this suggests a new team.
Management Team

Chris Kroeger

TITLE
CEO, President
COMPENSATION
$2M
AGE
50
TENURE
1.3 yrs

Michelle Dipp

TITLE
Co-Founder & Advisor
COMPENSATION
$1M
AGE
42
TENURE
7.7 yrs

Jonathan Gillis

TITLE
Senior VP of Finance & Treasurer
COMPENSATION
$477K
AGE
37
TENURE
1.5 yrs

Jon Tilly

TITLE
Co-Founder and Advisor
COMPENSATION
$99K
AGE
55
TENURE
7.7 yrs

Katherine Lefeber

TITLE
Vice President of Strategy & Operations

James Lillie

TITLE
Chief Scientific Officer
AGE
62
TENURE
0.9 yrs

Cara Mayfield

TITLE
Director of Corporate Communications

Lou Villalba

TITLE
Senior Vice President of Corporate Development
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the OvaScience board of directors in years:

5.5
Average Tenure
55
Average Age
  • The tenure for the OvaScience board of directors is about average.
Board of Directors

Jon Tilly

TITLE
Co-Founder and Advisor
COMPENSATION
$99K
AGE
55
TENURE
7.4 yrs

Rich Aldrich

TITLE
Co-Founder & Lead Independent Director
COMPENSATION
$55K
AGE
64
TENURE
2.8 yrs

Chris Kroeger

TITLE
CEO, President
COMPENSATION
$2M
AGE
50
TENURE
1.3 yrs

Jeff Capello

TITLE
Director
COMPENSATION
$62K
AGE
53
TENURE
6.8 yrs

John Howe

TITLE
Director
COMPENSATION
$183K
AGE
75
TENURE
3.5 yrs

David Sinclair

TITLE
AGE
48
TENURE
7.3 yrs

Mary Fisher

TITLE
Director
COMPENSATION
$52K
AGE
56
TENURE
5.5 yrs

Ernesto Bosch

TITLE

Klaus Buhler

TITLE

Gab Kovacs

TITLE
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess OvaScience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OvaScience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

3OS News

External News
Loading...
Simply Wall St News

3OS Company Info

Map
Description

OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women’s fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman’s egg production by isolating a woman’s own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman’s own EggPC cells. It also provides OvaXon for the prevention of inherited diseases for human and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Details
Name: OvaScience, Inc.
3OS
Exchange: DB
Founded: 2011
$23,386,977
35,826,429
Website: http://www.ovascience.com
Address: OvaScience, Inc.
9 4th Avenue,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM OVAS Common Stock Nasdaq Capital Market US USD 05. Oct 2012
DB 3OS Common Stock Deutsche Boerse AG DE EUR 05. Oct 2012
Number of employees
Current staff
Staff numbers
36
OvaScience employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/07 21:58
End of day share price update: 2018/12/07 00:00
Last estimates confirmation: 2018/03/15
Last earnings filing: 2018/11/09
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.